Lucid Diagnostics (LUCD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, to be held virtually at 11:00 a.m. Eastern time.
Stockholders can vote electronically using a 12-digit control number.
Proxy materials, including the annual report and proxy statement, are available online for review.
Voting matters and shareholder proposals
Election of three Class B directors to serve until the third succeeding annual meeting.
Proposal to amend the certificate of incorporation to increase authorized common stock by 100,000,000 shares, from 300,000,000 to 400,000,000.
Ratification of CBIZ CPAS P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Board recommends voting "FOR" all management proposals.
Board of directors and corporate governance
Three board seats (Class B) are up for election, with terms lasting until the third succeeding annual meeting.
Latest events from Lucid Diagnostics
- Shareholders will vote on director elections, capital increase, and auditor ratification, with board support.LUCD
Proxy filing30 Apr 2026 - Shareholders will vote on director elections, capital increase, and auditor ratification under strong governance.LUCD
Proxy filing20 Apr 2026 - Breakthrough non-endoscopic screening drives early esophageal cancer detection in a $60B market.LUCD
Company presentation8 Apr 2026 - Q4 2025 revenue and test volume surged, with VA and Medicare coverage set to boost future growth.LUCD
Q4 202526 Mar 2026 - Flexible $175M shelf and $25M ATM offering targets growth amid ongoing losses and dilution risk.LUCD
Registration filing26 Mar 2026 - All proposals, including director elections and share increases, were approved by shareholders.LUCD
AGM 20243 Feb 2026 - Record test growth and robust clinical data set the stage for expanded coverage and revenue.LUCD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Record test volume and strong clinical data drive growth, but funding and reimbursement risks remain.LUCD
Q2 20241 Feb 2026 - Innovative pre-cancer screening and reimbursement progress set the stage for strong growth.LUCD
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026